Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer

Inclusion Criteria:

* Patients must have persistent, recurrent, or primary Stage IVB carcinoma of the cervix not amenable to curative therapy with either surgery and/or radiation.
* Patients must have biopsy proven squamous cell, adenosquamous, or adenocarcinoma histology.
* Patients do not require measurable disease.
* Patients must have adequate organ function defined by laboratory work.
* Patients must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
* Patients must have recovered from any effects attributable to surgery, radiation, or chemoradiotherapy. A minimum of six weeks shall have passed since the last administration of chemoradiotherapy or three weeks for radiation therapy alone.
* Patients must be free of clinically significant infections.
* Patients must be age 19 or greater and have signed informed consent.

Exclusion Criteria:

* Patients who are pregnant or lactating.
* Patients with history of other malignancies (except non-melanoma skin cancer) within the last 5 years are ineligible.
* Patients with non-squamous, adenosquamous, or adenocarcinoma histology.
* Patients with bilateral hydronephrosis that cannot be alleviated by ureteral stents or percutaneous drainage.
* Patients currently receiving any or having received other investigational agents within the last 30 days are ineligible.
* Patients with known hypersensitivity to topotecan or cisplatin.
* Patients with craniospinal metastases.
* Patients with uncontrolled current illness including, but not limited to, ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, serious peripheral neuropathy, or psychiatric illness/social situations that would limit or preclude compliance with study requirements are ineligible.